Many people reported they felt like time was passing differently during the initial COVID-19 lockdowns. Researchers explore how the pandemic has contributed to the feeling of time distortion.
Researchers found hallmarks of damage caused by thinning and leaky blood vessels in brain samples of people after contracting COVID-19, but saw no evidence of SARS_CoV_2 in the tissue samples. Findings suggest the damage was not caused by a direct viral attack on the brain, but by the body's immune response to the infection.
Researchers have isolated a set of antibodies from a llama which show promise for the treatment of COVID-19. The NIH-CoVnB-112 nanoantibody bound to ACE2 receptors up to ten times stronger than other lab-produced antibodies. The nanoantibody stuck directly to the ACE2 receptor binding portion of the SARS_CoV-2 spike protein. The protein could be effective in preventing coronavirus infection.
SARS-CoV-2, the virus responsible for COVID-19 enters the brain via neurons in the olfactory mucosa.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
Researchers propose a strategy for repurposing geroprotectors, including rapamycin and metformin, as potential COVID-19 infection prevention methods.
